Drug Profile
Research programme: siRNA therapeutics - PreveCeutical Medical/UniQuest
Alternative Names: Dual gene therapy - PreveCeutical/UniQuestLatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator PreveCeutical Medical; UniQuest
- Developer Murdoch University; PreveCeutical Medical; QIMR Berghofer Medical Research Institute; UniQuest
- Class Antihyperglycaemics; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus; Obesity
Most Recent Events
- 28 May 2021 No recent reports of development identified for research development in Diabetes-mellitus in Australia (Parenteral)
- 28 May 2021 No recent reports of development identified for research development in Diabetes-mellitus in USA (Parenteral)
- 28 May 2021 No recent reports of development identified for research development in Obesity in Australia (Parenteral)